Fig. 1From: Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational studyConsort diagram displaying the progression of patients through the study protocol from initial assessment for eligibility to protocol completionBack to article page